Logo image of XAIR

BEYOND AIR INC (XAIR) Stock Fundamental Analysis

NASDAQ:XAIR - Nasdaq - US08862L1035 - Common Stock - Currency: USD

0.2135  +0.02 (+9.54%)

After market: 0.21 0 (-1.64%)

Fundamental Rating

3

XAIR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. While XAIR seems to be doing ok healthwise, there are quite some concerns on its profitability. XAIR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

XAIR had negative earnings in the past year.
XAIR had a negative operating cash flow in the past year.
In the past 5 years XAIR always reported negative net income.
In the past 5 years XAIR always reported negative operating cash flow.
XAIR Yearly Net Income VS EBIT VS OCF VS FCFXAIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -153.17%, XAIR is not doing good in the industry: 91.01% of the companies in the same industry are doing better.
XAIR has a worse Return On Equity (-296.42%) than 80.95% of its industry peers.
Industry RankSector Rank
ROA -153.17%
ROE -296.42%
ROIC N/A
ROA(3y)-76.83%
ROA(5y)-72.3%
ROE(3y)-149.03%
ROE(5y)-127.06%
ROIC(3y)N/A
ROIC(5y)N/A
XAIR Yearly ROA, ROE, ROICXAIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800 -1K

1.3 Margins

XAIR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XAIR Yearly Profit, Operating, Gross MarginsXAIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

XAIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
XAIR has more shares outstanding than it did 1 year ago.
XAIR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XAIR is higher compared to a year ago.
XAIR Yearly Shares OutstandingXAIR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XAIR Yearly Total Debt VS Total AssetsXAIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

XAIR has an Altman-Z score of -15.04. This is a bad value and indicates that XAIR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of XAIR (-15.04) is worse than 84.66% of its industry peers.
There is no outstanding debt for XAIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.04
ROIC/WACCN/A
WACC12.39%
XAIR Yearly LT Debt VS Equity VS FCFXAIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 3.56 indicates that XAIR has no problem at all paying its short term obligations.
XAIR's Current ratio of 3.56 is fine compared to the rest of the industry. XAIR outperforms 60.85% of its industry peers.
XAIR has a Quick Ratio of 3.12. This indicates that XAIR is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.12, XAIR is doing good in the industry, outperforming 64.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.56
Quick Ratio 3.12
XAIR Yearly Current Assets VS Current LiabilitesXAIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

XAIR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.23%, which is quite impressive.
XAIR shows a strong growth in Revenue. In the last year, the Revenue has grown by 337.48%.
The Revenue for XAIR have been decreasing by -31.56% on average. This is quite bad
EPS 1Y (TTM)50.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)337.48%
Revenue growth 3Y10.03%
Revenue growth 5Y-31.56%
Sales Q2Q%174.17%

3.2 Future

XAIR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.38% yearly.
XAIR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 187.93% yearly.
EPS Next Y58.42%
EPS Next 2Y33.81%
EPS Next 3Y22.38%
EPS Next 5YN/A
Revenue Next Year172.26%
Revenue Next 2Y212.53%
Revenue Next 3Y187.93%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XAIR Yearly Revenue VS EstimatesXAIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2023 2024 2025 2026 2027 10M 20M 30M
XAIR Yearly EPS VS EstimatesXAIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XAIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XAIR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XAIR Price Earnings VS Forward Price EarningsXAIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XAIR Per share dataXAIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

XAIR's earnings are expected to grow with 22.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.81%
EPS Next 3Y22.38%

More info and screens

0

5. Dividend

5.1 Amount

XAIR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEYOND AIR INC

NASDAQ:XAIR (5/1/2025, 5:20:02 PM)

After market: 0.21 0 (-1.64%)

0.2135

+0.02 (+9.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10 2025-02-10/amc
Earnings (Next)06-23 2025-06-23/amc
Inst Owners22.28%
Inst Owner Change0.09%
Ins Owners12.88%
Ins Owner Change11.95%
Market Cap18.85M
Analysts80
Price Target2.3 (977.28%)
Short Float %2.18%
Short Ratio0.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.71%
Min EPS beat(2)3.34%
Max EPS beat(2)8.09%
EPS beat(4)4
Avg EPS beat(4)13.48%
Min EPS beat(4)3.34%
Max EPS beat(4)25.85%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)7
Avg EPS beat(12)-11.22%
EPS beat(16)8
Avg EPS beat(16)-11.83%
Revenue beat(2)1
Avg Revenue beat(2)-6.11%
Min Revenue beat(2)-24.93%
Max Revenue beat(2)12.72%
Revenue beat(4)1
Avg Revenue beat(4)-16.66%
Min Revenue beat(4)-38.33%
Max Revenue beat(4)12.72%
Revenue beat(8)1
Avg Revenue beat(8)-39.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.44%
EPS NY rev (1m)0%
EPS NY rev (3m)4.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.23
P/FCF N/A
P/OCF N/A
P/B 1.07
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.03
BVpS0.2
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -153.17%
ROE -296.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.83%
ROA(5y)-72.3%
ROE(3y)-149.03%
ROE(5y)-127.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 210.25%
Cap/Sales 208.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.56
Quick Ratio 3.12
Altman-Z -15.04
F-Score5
WACC12.39%
ROIC/WACCN/A
Cap/Depr(3y)382.11%
Cap/Depr(5y)319.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y58.42%
EPS Next 2Y33.81%
EPS Next 3Y22.38%
EPS Next 5YN/A
Revenue 1Y (TTM)337.48%
Revenue growth 3Y10.03%
Revenue growth 5Y-31.56%
Sales Q2Q%174.17%
Revenue Next Year172.26%
Revenue Next 2Y212.53%
Revenue Next 3Y187.93%
Revenue Next 5YN/A
EBIT growth 1Y22.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.61%
EBIT Next 3Y47.01%
EBIT Next 5YN/A
FCF growth 1Y-39.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.35%
OCF growth 3YN/A
OCF growth 5YN/A